MN-25

MN-25 (UR-12) is a drug invented by Bristol-Myers Squibb,^[1] that acts as a reasonably selective agonist of peripheral cannabinoid receptors.^[2] It has moderate affinity for CB₂ receptors with a K_i of 11 nM, but 22x lower affinity for the psychoactive CB₁ receptors with a K_i of 245 nM. The indole 2-methyl derivative has the ratio of affinities reversed however, with a K_i of 8 nM at CB₁ and 29 nM at CB₂,^[3][4] which contrasts with the usual trend of 2-methyl derivatives having increased selectivity for CB₂ (cf. JWH-018 vs JWH-007, JWH-081 vs JWH-098).^[5][6]

MN-25

Clinical data
Other names	N-[(S)-Fenchyl]-1-[2-(morpholin-4-yl)ethyl]-7-methoxyindole-3-carboxamide
Legal status
Legal status	CA: Schedule II DE: NpSG (Industrial and scientific use only) UK: Class B
Identifiers
IUPAC name 7-methoxy-1-(2-morpholin-4-ylethyl)-N-[(1R,3S,4S)-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]indole-3-carboxamide
CAS Number	501926-82-5 Y 2-methyl derivative: 501927-29-3
PubChem CID	71308243
ChemSpider	26286811 Y
UNII	8WXU5YRE25
ChEMBL	ChEMBL3234671
Chemical and physical data
Formula	C26H37N3O3
Molar mass	439.600 g·mol−1
3D model (JSmol)	Interactive image
SMILES COC1=C(N(CCN2CCOCC2)C=C3C(N[C@H]4[C@@]5(C)CC[C@H](C5)C4(C)C)=O)C3=CC=C1
InChI InChI=1S/C26H37N3O3/c1-25(2)18-8-9-26(3,16-18)24(25)27-23(30)20-17-29(11-10-28-12-14-32-15-13-28)22-19(20)6-5-7-21(22)31-4/h5-7,17-18,24H,8-16H2,1-4H3,(H,27,30)/t18-,24-,26+/m1/s1 Y Key:VQGDMQICNRCQEH-UFKXBGGNSA-N Y
(verify)

Chemically, it is closely related to another indole-3-carboxamide synthetic cannabinoid, Org 28611, but with a different cycloalkyl substitution on the carboxamide, and the cyclohexylmethyl group replaced by morpholinylethyl, as in JWH-200 or A-796,260. Early compounds such as these have subsequently led to the development of many related indole-3-carboxamide cannabinoid ligands.^{[7][8][9][10]}

See also

• A-834,735
• AB-001
• AM-1221
• BMS-F
• CUMYL-PEGACLONE
• JTE 7-31
• JWH-203
• MDA-19
• SR-144,528
• UR-144